| TTM
|
12/31/2025
|
12/31/2024
|
|
|---|---|---|---|
| Total Revenue
|
4,435 | 6,741 | 14,936 |
| Selling, General and Administrative Expenses
|
-6,229 | -6,112 | -6,400 |
|
Research and Development Expenses
|
-32,015 | -40,507 | -41,069 |
|
Operating Income/Expenses
|
-38,244 | -46,619 | -47,469 |
|
Total Operating Profit/Loss
|
-33,809 | -39,878 | -32,533 |
| Total Net Finance Income/Expense
|
3,699 | 4,799 | 6,154 |
| Irregular Income/Expenses
|
-121 | -1,528 | 0 |
|
Other Income/Expense, Non-Operating
|
-50 | -102 | -117 |
|
Non-Operating Income/Expenses, Total
|
3,528 | 3,169 | 6,037 |
|
Pretax Income
|
-30,281 | -36,709 | -26,496 |
|
Provision for Income Tax
|
249 | 249 | -7 |
|
Net Income from Continuing Operations
|
-30,032 | -36,460 | -26,503 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-30,032 | -36,460 | -26,503 |
|
Net Income after Non-Controlling/Minority Interests
|
-30,032 | -36,460 | -26,503 |
|
Net Income Available to Common Stockholders
|
-30,032 | -36,460 | -26,503 |
|
Diluted Net Income Available to Common Stockholders
|
-30,032 | -36,460 | -26,503 |
| Basic EPS
|
-1.04 | -1.25 | -0.88 |
| Diluted EPS
|
-1.04 | -1.25 | -0.88 |
|
Basic Weighted Average Shares Outstanding
|
29,120.40 | 29,120.40 | 30,152.82 |
|
Diluted Weighted Average Shares Outstanding
|
29,120.40 | 29,120.40 | 30,152.82 |
| Income Statement, Supplemental
|
|||
|
EBIT
|
-33,980 | -41,508 | -32,650 |
|
EBITDA
|
-33,006 | -40,318 | -31,474 |
|
Normalized EBITDA
|
-31,930 | -37,692 | -30,683 |
|
Normalized Income
|
-28,964.85 | -33,852.38 | -25,914.73 |
|
Total Unusual Items
|
1,076 | 2,626 | 791 |
|
Total Unusual Items Excluding Goodwill
|
1,076 | 2,626 | 791 |
|
Tax Effect of Unusual Items
|
8.85 | 18.38 | 202.73 |
|
Tax Rate, Calculated
|
0.01 | 0.01 | 0.26 |
12/31/2024 - 10/23/2026
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade